A Study of LY3200882 in Participants With Solid Tumors

NCT02937272 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

223

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: LY3200882
DRUG: LY3300054
DRUG: Gemcitabine
DRUG: nab-Paclitaxel
DRUG: Cisplatin
RADIATION: Intensity Modulated Radiotherapy

Sponsor

Eli Lilly and Company